Presentation is loading. Please wait.

Presentation is loading. Please wait.

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Published byNoreen Kerrie Stevenson Modified over 6 years ago

Similar presentations

Presentation on theme: "Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K"— Presentation transcript:

1 Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial 
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K. Scadding, MD, Philippe Gevaert, MD, Shuaib Nasser, MD, Stephen R. Durham, MD, Marjolein E. Cornet, MD, Harsha H. Kariyawasam, PhD, Jane Gilbert, MSc, Daren Austin, PhD, Aoife C. Maxwell, PhD, Richard P. Marshall, PhD, Wytske J. Fokkens, PhD  Journal of Allergy and Clinical Immunology  Volume 140, Issue 4, Pages e14 (October 2017) DOI: /j.jaci Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Patient flow through the study. *One patient randomized to the mepolizumab group received placebo in error; this patient is included in the safety population for placebo. †Protocol deviations were incorrect treatment/dose (n = 3), did not meet inclusion criteria (n = 1), and smoked during the study (n = 1). ‡Before a protocol amendment that discontinued recruitment to the extension study, patients were given the option to enter the extension study. Patients were eligible to enter the extension if they were judged to no longer have a requirement for surgery according to the criteria defined in Table E2. Results from the extension phase are not presented because of low patient numbers. PP, Per-protocol. Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Efficacy. A, Percentage of patients meeting the criteria for surgery over time (missing data imputed as nonresponders). B, Mean nasal polyposis severity VAS score for nasal polyposis. C, Least squares (LS) mean change from baseline in total endoscopic nasal polyp score (ITT population [post hoc output using last observation carried forward]). *P ≤ .05 and **P ≤ .01. Bars represent 95% CIs. VAS, 0 to 10 cm (0 = not troublesome and 10 = worst possible troublesome). Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Adjusted mean individual symptom VAS scores over time for rhinorrhea (A), mucus in throat (B), nasal blockage (C), and loss of smell (D; ITT population [adjusted for baseline, visit, treatment group, and visit-treatment group interaction]). Bars represent 95% CIs. *P ≤ .05, **P ≤ .01, and ***P ≤ .001. VAS, 0 to 10 cm (0 = not troublesome and 10 = worst possible troublesome). Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E1 Patients in the mepolizumab group achieving a 1-point or greater improvement in total endoscopic nasal polyp score at Week 25 according to baseline eosinophil count (ITT population; post hoc analysis). Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E2 Adjusted means for SNOT-22 results at Week 25 (ITT population). Missing data are not imputed; bars represent SEs. *P = .005. Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Nasal challenge with allergen leads to maxillary sinus inflammation

Nasal challenge with allergen leads to maxillary sinus inflammation
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery  Albertien A.C. Aukema,
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Rhinosinusitis: Developing guidance for clinical trials

Rhinosinusitis: Developing guidance for clinical trials
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,

Oral steroids and doxycycline: Two different approaches to treat nasal polyps  Thibaut Van Zele, MD, PhD, Philippe Gevaert, MD, PhD, Gabriele Holtappels,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Similar presentations

Ads by Google